Information Provided By:
Fly News Breaks for June 18, 2018
CYTK
Jun 18, 2018 | 07:15 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $24 after the company announced Phase 2 study results using reldesemtiv in spinal muscular atrophy patients. The analyst says the data presented exceeded his expectations. He keeps a Buy rating on Cytokinetics.
News For CYTK From the Last 2 Days
There are no results for your query CYTK